{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T15:00:51Z","timestamp":1788447651935,"version":"build-2803163510"},"reference-count":36,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Binge eating disorder (BED) is a common psychiatric condition associated with psychological and cardiometabolic morbidity. Psychotherapy remains a core treatment modality while pharmacologic agents such as lisdexamfetamine, selective\u2010serotonin reuptake inhibitors (SSRIs), and topiramate demonstrate variable efficacy and tolerability. Incretin therapies\u2014specifically glucagon\u2010like peptide\u20101 receptor agonists (GLP\u20101 RAs) and dual glucose\u2010dependent insulinotropic polypeptide (GIP) and GLP\u20101 RA\u2014originally developed for type 2 diabetes mellitus (T2DM) and obesity, are an emerging therapy of interest for BED due to their effects on satiety, appetite regulation, and reward\u2010driven eating. This systematic review examines current data surrounding the efficacy of incretin therapies in treating BED and discusses potential mechanisms underlying their effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This systematic review was registered with PROSPERO (CRD42024615851) and conducted in accordance with PRISMA 2020 guidelines. Comprehensive searches were performed across MEDLINE, Embase, PsycINFO, Scopus, and Cochrane CENTRAL from inception to December 2024. Eligible studies included human trials evaluating GLP\u20101 RAs or dual GLP\u20101\/GIP agonists in patients with diagnosed BED or binge eating behaviors. Data were extracted on study design, interventions, eating disorder outcomes, psychiatric symptoms, weight, and cardiometabolic measures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 1125 screened records, 12 studies met inclusion criteria. Interventions studied included liraglutide, semaglutide, and dulaglutide, with sample sizes generally &lt;\u200975 participants. Despite heterogeneity in study design and outcome measures, consistent reductions in binge eating behaviors were observed, reflected by improvements in Binge Eating Scale scores, reductions in binge frequency, and remission rates. GLP\u20101 RAs were also associated with significant reductions in body weight (\u22123 to \u221224\u2009kg), BMI, and improvements in glycemic control among individuals with diabetes. Adverse effects were primarily gastrointestinal, with no new psychiatric safety concerns identified.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>GLP\u20101 RAs may offer dual therapeutic benefits for BED, reducing binge eating behaviors while addressing comorbid obesity and metabolic consequences. However, available evidence is limited by small sample sizes, heterogeneous methods, and short follow\u2010up durations. Larger randomized controlled trials using standardized diagnostic criteria and validated psychiatric measures are warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/phar.70135","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T07:16:01Z","timestamp":1775632561000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Incretin\u2010Based Therapies for the Treatment of Binge Eating\u2014A Systematic Review"],"prefix":"10.1002","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5929-5590","authenticated-orcid":false,"given":"Raechel T.","family":"White","sequence":"first","affiliation":[{"name":"USF Taneja College of Pharmacy, University of South Florida  Tampa Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penelope","family":"Henriquez","sequence":"additional","affiliation":[{"name":"USF Taneja College of Pharmacy, University of South Florida  Tampa Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britnee","family":"Innocent","sequence":"additional","affiliation":[{"name":"USF Taneja College of Pharmacy, University of South Florida  Tampa Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2199-2286","authenticated-orcid":false,"given":"Krystal","family":"Bullers","sequence":"additional","affiliation":[{"name":"USF Health Libraries, University of South Florida  Tampa Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8993-9764","authenticated-orcid":false,"given":"Amre","family":"Elmaoued","sequence":"additional","affiliation":[{"name":"University of New Mexico College of Pharmacy  Albuquerque New Mexico USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,4,8]]},"reference":[{"key":"e_1_2_11_2_1","volume-title":"Diagnostic and Statistical Manual of Mental Disorders. DSM Library","year":"2022"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/YCO.0000000000000750"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpsy.2024.100274"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpr.2017.12.004"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.23180001"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2015.275"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12888\u2010022\u201004005\u2010y"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2307563"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2025.01.021"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411892"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.24945"},{"key":"e_1_2_11_13_1","unstructured":"R.White A.Elmaoued K.Buller P.Henriquez andB.Innocent \u201cPROSPERO. Incretin Therapies in Binge Eating Disorder \u201dPROSPERO (2024) https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD42024615851."},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2016.01.021"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928"},{"key":"e_1_2_11_16_1","unstructured":"\u201cCASP Checklists\u2013Critical Appraisal Skills Programme \u201dCASP\u2013Critical Appraisal Skills Programme accessed October 6 2025 https:\/\/casp\u2010uk.net\/casp\u2010tools\u2010checklists\/."},{"key":"e_1_2_11_17_1","unstructured":"J.Martin \u201cCritical Appraisal Checklist for Case Reports \u201d(2017) Joanna Briggs Institute."},{"key":"e_1_2_11_18_1","unstructured":"\u201cCritical Appraisal Tools \u201daccessed October 6 2025 https:\/\/www.cebm.ox.ac.uk\/resources\/ebm\u2010tools\/critical\u2010appraisal\u2010tools."},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.obpill.2023.100080"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.orcp.2015.03.005"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.3109\/07435800.2014.966385"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/oby.22653"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2020.03.009"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.3390\/metabo12020147"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.physbeh.2022.113967"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/osp4.619"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00592\u2010024\u201002392\u20100"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1080\/10550887.2024.2315365"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/imj.16499"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.4274\/jcrpe.galenos.2024.2023\u201010\u201010"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcte.2024.100333"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/eat.20057"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/0005\u20107967(94)00075\u2010u"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005650\u2010200412000\u201000006"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525\u20101497.2001.016009606.x"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598\u2010024\u201075965\u20102"},{"key":"e_1_2_11_37_1","unstructured":"\u201cVYVANSE (Lisdexamfetamine Dimesylate) Capsules for Oral Use CII.\u201d"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.70135","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/phar.70135","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.70135","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T10:40:18Z","timestamp":1778928018000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.70135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,8]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1002\/phar.70135"],"URL":"https:\/\/doi.org\/10.1002\/phar.70135","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,8]]},"assertion":[{"value":"2025-10-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70135"}}